MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

48.87 -1.06 (-2.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
News headline image
5 Best Stocks to Buy if You Have $100 to Spend ↗
My son became an investor this year, taking a job that pays more than his single, frugal lifestyle consumes. He asked me what stocks he might buy with 
Via InvestorPlace
News headline image
The 3 Leaders of the Gene Editing Revolution ↗
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
News headline image
7 Moonshot Investments Upending a $10 Trillion Industry ↗
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
News headline image
7 Best Biotech Stocks to Buy in July 2022 ↗
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
News headline image
Analyst Ratings for CRISPR Therapeutics ↗
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them? ↗
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say. 
Via Investor's Business Daily
News headline image
Jim Cramer Says This Company Isn't Making Money ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is hearing nothing but positives of late about Nokia Corp (NYSE: NOK) over the previous four weeks. "I think it’s right to buy," he added. 
Via Benzinga
News headline image
Evercore ISI Group Downgrades CRISPR Therapeutics: Here's What You Need To Know ↗
Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics... 
Via Benzinga
News headline image
Why CRISPR Therapeutics Stock Is Falling ↗
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading lower Wednesday after several analysts adjusted price targets on the stock following the company's Innovation Day. 
Via Benzinga
News headline image
Chardan Capital Maintains Buy Rating for CRISPR Therapeutics: Here's What You Need To Know ↗
Chardan Capital has decided to maintain its Buy rating of CRISPR Therapeutics (NASDAQ:CRSP) and lower its price target from $168.00 to $164.00. Shares of CRISPR Therapeutics are trading down 8.24% over... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Bear Market Rally Lifts HealthCare Stocks Off Bottom ↗
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma. 
Via Talk Markets
News headline image
CNBC's Final Trades: Ethereum, Charles Schwab, Clean Energy, Boeing And This Biotech Stock ↗
On CNBC’s “Halftime Report Final Trades,” Kevin O'Leary, known as "Mr. 
Via Benzinga
News headline image
93 Biggest Movers From Yesterday ↗
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
News headline image
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases? ↗
Crispr and Vertex tested their gene-edited drug in two blood diseases. 
Via Investor's Business Daily
News headline image
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive ↗
CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic... 
Via Benzinga
News headline image
70 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
News headline image
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing ↗
The company is using a different approach to tackle the blood disease. 
Via Investor's Business Daily
News headline image
7 No-Brainer Biotech Stocks to Add to Your Buy List ↗
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. 
Via InvestorPlace
News headline image
7 Oversold Stocks to Buy Right Now ↗
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price. 
Via InvestorPlace
News headline image
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
IBD Tech Leader Vertex Snags Upgrade As Non-Cystic Fibrosis Drugs Crystallize ↗
One analyst expects multiple new drug launches between 2024-26. 
Via Investor's Business Daily
News headline image
Cathie Wood Provides Lesson of the Day: Don't Invest in Fairytale Stocks ↗
Tesla is no longer the No.1 holding of Cathie Wood's ARK. Let's see what's inside. 
Via Talk Markets
Why Orphan Drug Designation Offers Several Benefits
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we... 
Via FinancialNewsMedia
News headline image
Analyst Ratings for CRISPR Therapeutics ↗
Over the past 3 months, 11 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
How to Buy Stocks in a Recession ↗
The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward. 
Via InvestorPlace
News headline image
5 Cathie Wood Stocks to Buy Now ↗
ARK Invest funds led by Cathie Wood seek long-term capital growth and focus mainly on disruptive innovation. Here's a look a five related stocks to consider. 
Via InvestorPlace
News headline image
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis ↗
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped. 
Via Investor's Business Daily
News headline image
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data ↗
 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story